JACC:联合心肌I型胶原相关标志物可预测房颤发病和复发风险

2019-04-08 不详 MedSci原创

心衰患者的循环生物标志物I型心肌胶原交联或CCL+和心肌I型胶原沉积或CD+均有所升高,且与不良预后呈相关性。本研究的目的旨在评估生物标志物CCL+CD+的结合能否预测房颤患者的结局。本研究对242名心衰患者(研究1)和150名房颤患者(研究2)的血清样本进行了生物标志物的分析,根据生物标志物的阈值,将患者分成三类(CCL?CD?, CCL+CD? 或 CCL?CD+, 和CCL+CD+),并对7

心衰患者的循环生物标志物I型心肌胶原交联或CCL+和心肌I型胶原沉积或CD+均有所升高,且与不良预后呈相关性。本研究的目的旨在评估生物标志物CCL+CD+的结合能否预测房颤患者的结局。

本研究对242名心衰患者(研究1)和150名房颤患者(研究2)的血清样本进行了生物标志物的分析,根据生物标志物的阈值,将患者分成三类(CCL-CD-, CCL+CD- 或 CCL-CD+, 和CCL+CD+),并对71名研究2中的患者进行了左心房电解剖高密度标测。在研究1中,53.7%的患者基线水平时就有房颤,19.6%的患者发展为房颤(平均随访时间为5.5年),与CCL-CD-患者相比,CCL+CD+患者的房颤风险更高。在研究2中,在消融术后1年中,29.3%的患者有复发性房颤,与CCL-CD-患者相比,CCL+CD+患者的房颤复发风险更高,CCL+CD+的组合对相关的协变量增加了增量预测值。另外,CCL+CD+患者左心房电压低于其余患者(P=0.005)。

研究结果显示,反映了I型心肌胶原过度交联和沉积的循环生物标志物的组合与房颤的发生风险和术后复发风险呈相关性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854353, encodeId=57e01854353c1, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jul 19 02:33:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905523, encodeId=e5771905523db, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Nov 23 16:33:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841378, encodeId=b76d18413e8fb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jan 19 14:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326174, encodeId=2c3c13261e401, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 10 00:33:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-07-19 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854353, encodeId=57e01854353c1, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jul 19 02:33:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905523, encodeId=e5771905523db, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Nov 23 16:33:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841378, encodeId=b76d18413e8fb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jan 19 14:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326174, encodeId=2c3c13261e401, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 10 00:33:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854353, encodeId=57e01854353c1, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jul 19 02:33:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905523, encodeId=e5771905523db, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Nov 23 16:33:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841378, encodeId=b76d18413e8fb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jan 19 14:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326174, encodeId=2c3c13261e401, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 10 00:33:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854353, encodeId=57e01854353c1, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jul 19 02:33:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905523, encodeId=e5771905523db, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sat Nov 23 16:33:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841378, encodeId=b76d18413e8fb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jan 19 14:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326174, encodeId=2c3c13261e401, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 10 00:33:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]

相关资讯

JAHA:不同手术方式对主动脉缩窄患者预后的影响

主动脉缩窄(COA)即使接受了合适的治疗也会发生血管功能不全,但COA的治疗方法对血管功能的影响尚不清楚。本研究的目的旨在评估和比较外科手术、球囊扩张(BD)和支架植入治疗COA对血管功能的影响。本研究纳入了75例COA患者(28例为外科手术,23例为BD,24例支架植入),患者入组时的年龄、COA严重程度、压差梯度和代谢水平相似,但接受治疗时的年龄不尽相同。系统性高血压、主动脉僵硬度、内皮功能和

JAHA:他汀类药物依从性降低的心梗患者死亡风险**

许多急性心梗(AMI)后的老年患者在他汀类药物的依从性方面有所变化,但其与死亡率的相关性尚不清楚。本研究纳入了101011名2008-2010年年龄≥66岁的AMI住院患者,并对患者AMI前180天和AMI后180天的他汀类药物依从性进行了评估,分为非常不依从、轻中度不依从和依从三类。经过平均18个月时间的随访,20%的患者依从性明显提高,16%有所降低,14%患者无论AMI前还是AMI后均为不依

J Thromb Haemost:慢性免疫性血小板减少症患者心血管和出血结局

在cITP患者中,心血管事件的1年风险为1%-2%,而近1%的患者在1年内出现了出血事件。各种血小板水平均发生心血管事件,而低血小板计数与出血危害增加有关。心血管和出血事件是死亡率的强预后因素。

JACC:PET/MRI在检测动脉炎症中的应用

动脉粥样硬化是一种慢性炎症疾病,但是尚缺乏动脉早期炎症的检测方法。本研究的目的旨在通过混合18F-氟脱氧葡萄糖(18F-FDG)正电子发射断层扫描/磁共振成像(PET/MRI)方法检测血管炎症的可行性。本研究纳入了PESA临床研究中的755名(40-54岁,男性占83.7%)通过血管内超声检测有斑块的患者,并对其颈动脉、主动脉和股动脉进行了PET/MRI检测。最终,在48.2%的患者中检测到动脉炎

JACC:新型针管式导管消融方法治疗难治性室性心律失常

导管消融术对大部分药物难治性室性心律失常(VA)是有效的,然而对于部分异位起搏点位于心肌深处的VA来说,常规的心内膜和心外膜方法效果不佳,这类病人尚无有效治疗方法。本研究的目的旨在评估一种能够瞄准深部心律失常位点的新型可伸缩的27G针管的安全性和可行性。本研究纳入了31例之前至少接受过一次失败的导管消融术的持续性室性心律失常患者,对其进行了新型针管式消融,经过平均每个患者15针治疗后,73%的VT

JAHA:半乳凝素-3与肥胖患者的代谢性心脏病风险相关

肥胖是心衰伴保留型射血分数的先兆,本研究的目的旨在评估半乳凝素-3(GAL3)、卵泡抑素样3肽(FSTL3)和NT-proBNP(N-末端前B型钠尿肽)在预测年轻肥胖患者代谢性心脏疾病(MHD)的价值。本研究纳入了250例无症状的肥胖患者和21例非肥胖对照,并对其进行超声心动图检测,其中有94例患者诊断为MHD阳性患者(MHD-POS):舒张功能异常或左室肥厚和肺动脉收缩压≥35mmHg。没有这些